Cilag gets global rights to argenx's cusatuzumab
Argenx SE licensed Janssen’s Cilag GMBH International exclusive global rights to its cusatuzumab (ARGX110) in blood cancers.
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com